The selective BRAF inhibitors vemurafenib (Zelboraf, Roche/Plexxikon) and dabrafenib (Tafinlar, GlaxoSmithKline) have significantly improved survival in patients with BRAF V600–mutant metastatic ...

(Top) Melanoma develops resistance to BRAF inhibitors, leading to cancer recurrence. (Bottom) By combining polyamine biosynthesis inhibition with BRAF inhibitors, the recurrence of cancer can be ...

In patients with skin or lung cancer, drugs that inhibit BRAF (v-raf murine sarcoma viral oncogene homolog B) mutations increase the risk for uveitis dramatically compared with conventional ...

“Inhibitors of GSK3β reduce the cell viability of BRAFi-resistant melanoma cell lines and thus may holds promise as a novel strategy to overcome BRAFi resistance and melanoma progression” “Inhibitors ...

For the 40% or so of patients with BRAF -mutant melanoma, two important questions have been addressed through a series of well-designed prospective clinical trials. First, is it beneficial to combine ...

Purpose Dabrafenib (GSK2118436) is a potent inhibitor of mutated BRAF kinase. Our multicenter, single-arm, phase II study assessed the safety and clinical activity of dabrafenib in BRAFV600E/K ...

A new research perspective was published in Oncotarget, Volume 16, on April 4, 2025, titled "GSK3β activation is a key driver of resistance to Raf inhibition in BRAF mutant melanoma cells." In this ...

A new collaborative study led by researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham), published today in Cell Reports, provides new insight into the molecular changes that lead ...

For patients with advanced melanoma without BRAF mutation who no longer respond to immune checkpoint inhibitors, treatment ...

Dr. Inderjit Mehmi and Dr. Omid Hamid from the Angeles Clinic, explain how therapies like targeted therapies, immunotherapy and T-cell therapies are improving outcomes for patients with advanced ...